Bone lesion

Bone lesions represent localized structural abnormalities in bone tissue, typically manifesting as either pathological bone loss (osteolytic) or abnormal bone growth (osteoblastic). These lesions are not specific molecular targets themselves but are clinical and pathological manifestations resulting from the dysregulation of bone remodeling, frequently triggered by multiple myeloma or metastatic cancers such as breast and prostate cancer (StatPearls, 2023). The underlying pathology often involves a "vicious cycle" where tumor-secreted factors, such as RANK ligand (RANKL) and Dickkopf-1 (DKK1), stimulate osteoclast-mediated resorption or inhibit osteoblast-mediated bone formation (NIH/PMC, 2011, 2024). Therapeutic intervention focuses on targeting the molecular drivers of these lesions to prevent skeletal-related events like fractures, spinal cord compression, and severe pain. Common treatments include bisphosphonates, which inhibit osteoclast function by affecting farnesyl pyrophosphate synthase, and monoclonal antibodies like denosumab, which neutralizes RANKL to arrest bone destruction (Clinical Cancer Research, 2011).

Other names

Osteolytic lesionOsteoblastic lesionSkeletal lesionBone metastasisBone destruction

Therapeutic agents address bone lesions by targeting the underlying molecular pathways of bone remodeling. Bisphosphonates bind to hydroxyapatite and inhibit farnesyl pyrophosphate synthase (FPPS) within osteoclasts to reduce bone resorption. Denosumab acts as a monoclonal antibody that binds to and neutralizes RANK ligand (RANKL), thereby preventing the activation of the RANK receptor on osteoclast precursors. Sclerostin inhibitors like romosozumab promote bone formation by activating the Wnt signaling pathway in osteoblasts.